Pfizer in early-stage talks to acquire cancer drugmaker Seagen
Seagen has developed drugs like Adcetris, Tivdak, and Padcev based on its proprietary ADC technology
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Feb 23
Seagen has developed drugs like Adcetris, Tivdak, and Padcev based on its proprietary ADC technology
27 Feb 23
The positive opinion was adopted on the basis of a phase 3 trial that showed superior survival outcomes…
24 Feb 23
Previously referred to as efanesoctocog alfa, ALTUVIIIO is approved for routine prophylaxis and on-demand treatment to control bleeding…
23 Feb 23
The approval was based on the ELEVATE-PLUS trials, which established the bioequivalence between 100mg of acalabrutinib in tablet…
22 Feb 23
Our goal is to provide advice in nutrition and lifestyle medicine in order to empower people, improve quality…
22 Feb 23
The US drugmaker’s regulatory filings for maternal immunization are supported by the results of the Phase 3 trial…
22 Feb 23
In the early-stage trial, the Modi-1 vaccine candidate demonstrated a partial response and stable disease in patients having…
21 Feb 23
AdimFlu-S (QIS) was approved by the China National Medical Products Administration in January 2022 for use in individuals…
20 Feb 23
The approval is based on clinically meaningful and statistically significant improvements in proteinuria in comparison to an active…
17 Feb 23
The FDA granted priority review for Pfizer’s sNDA for the investigational drug combination for the treatment of mCRPC